Drug Profile
Elacestrant - Menarini
Alternative Names: ORSERDU; RAD 1901Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Menarini; Radius Health Inc.; Stemline Therapeutics
- Class Amines; Antineoplastics; Ethers; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 negative breast cancer
- Discontinued Vasomotor symptoms
Most Recent Events
- 11 Dec 2023 Initial adverse events data from a phase I/II trial in HER2-negative-breast-cancer presented at the San Antonio Breast Cancer Symposium (SABCS-2023)
- 07 Nov 2023 Menarini enters into exclusive sub-licensing agreement with SciClone Pharmaceuticals to develop and commercialize elacestrant for Breast cancer in China
- 06 Nov 2023 Stemline Therapeutics plans a phase I trial for Liver disorders in January 2024 (PO, Tablets) (NCT06126575)